A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 14-Day Repeated-Dose Administration of Thiamphenicol (RUX 122) in Healthy Subjects

The purpose of this study is to determine if two-weeks of dosing with thiamphenicol is safe and is able to change the levels of certain pre-specified biomarkers in nervous tissue taken from the nasal passages.

Start Date01 Jul 2007

Sponsor / Collaborator

Psyadon Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Thiamphenicol

100 Translational Medicine associated with Thiamphenicol

100 Patents (Medical) associated with Thiamphenicol

689

Literatures (Medical) associated with Thiamphenicol

31 Dec 2024·Journal of Dermatological Treatment

A pediatric case of dupilumab-induced pustular psoriasis

Article

Author: Dang, Nan ; Zheng, Huiwen ; Ren, Yunqing

Dupilumab is a novel treatment agent for moderate to severe atopic dermatitis (AD) with few adverse effects. Drug-induced psoriasiform lesions are rare.We report a 4-year-old boy with AD who developed pustular psoriasis during treatment with dupilumab.Pustular psoriasis appeared within 1 week of treatment and worsened in the second week. After stopping dupilumab administration, topical corticosteroids (desonide and mometasone furoate creams) and oral desloratadine without relief. Pustular psoriasis was confirmed by pathological examination, and thiamphenicol was administered. After 2 weeks of treatment, the lesions nearly resolved without recurrence in 1-year follow-up.Dupilumab-induced pustular psoriasis is rare in children.

01 Nov 2024·Environmental Toxicology and Chemistry

Photolysis Products of Fluorinated Pharmaceuticals: A Combined Fluorine Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry Approach

Article

Author: Bhat, Akash P. ; Pomerantz, William C.K. ; Mundhenke, Thomas F. ; Arnold, William A.

AbstractThe aqueous photolysis of four pharmaceuticals with varying fluorinated functional groups was assessed under neutral, alkaline, advanced oxidation, and advanced reduction conditions with varying light sources. Solar simulator quantum yields were 2.21 × 10−1 mol Ei−1 for enrofloxacin, 9.36 × 10−3 mol Ei−1 for voriconazole, and 1.49 × 10−2 mol Ei−1 for flecainide. Florfenicol direct photolysis was slow, taking 150 h for three degradation half‐lives. Bimolecular rate constants between pharmaceuticals and hydroxyl radicals were 109 to 1010 M−1 s−1. Using a combined quantitative fluorine nuclear magnetic resonance spectroscopy (19F‐NMR) and mass spectrometry approach, fluorine mass balances and photolysis product structures were elucidated. Enrofloxacin formed a variety of short‐lived fluorinated intermediates that retained the aryl F motif. Extended photolysis time led to complete aryl F mineralization to fluoride. The aliphatic F moiety on florfenicol was also mineralized to fluoride, but the resulting product was a known antibiotic (thiamphenicol). For voriconazole, the two aryl Fs contributed more to fluoride production compared with the heteroaromatic F, indicating higher stability of the heteroaromatic F motif. The two aliphatic CF3 moieties in the flecainide structure remained intact under all conditions, further supporting the stability of these moieties found in per‐ and polyfluoroalkyl substances under a variety of conditions. The advanced treatment conditions generating hydroxyl radicals or hydrated electrons accelerated the degradation, but not the defluorination, of flecainide. The combination of 19F‐NMR and mass spectrometry proved powerful in allowing identification of fluorinated products and verifying the functional groups present in the intermediates and products. The results found in the present study will aid in the understanding of which fluorinated functional groups should be incorporated into pharmaceuticals to ensure organofluorine byproducts are not formed in the environment and help determine the water‐treatment processes that effectively remove specific pharmaceuticals and more generally fluorinated motifs. Environ Toxicol Chem 2024;43:2285–2296. © 2023 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.

29 Oct 2024·Environmental Science & Technology

Customizable Three-Dimensional Printed Zerovalent Iron: An Efficient and Reusable Fenton-like Reagent for Florfenicol Degradation

Article

Author: Peng, Ping’an ; Li, Shunlu ; Yu, Hongdie ; Li, Dan ; Xu, Jianhui ; Yang, Sen ; Wang, Heli ; Zhang, Yunfei ; Yang, Qian ; Wu, Junhong ; Fu, Yibo ; Zhong, Yin ; Hong, Wentao ; Chen, Shenggui ; Qiu, Mulan

Zerovalent iron (Fe⁰)-based Fenton-like technology has great potential for treating recalcitrant organic pollutants (ROPs) in wastewater. However, rapidly and precisely manufacturing Fe⁰-based materials with the desired geometries is challenging. Herein, novel three-dimensional printed Fe⁰ (3DP-Fe⁰) and bimetallic 3DP-Ni/Fe⁰ were customized by 3D printing for efficient Fenton-like degradation of florfenicol (FLO), a typical antibiotic in wastewater. 3DP-Ni/Fe⁰ with hydrogen peroxide (H₂O₂) exhibited superior reactivity toward FLO than 3DP-Fe⁰, generating hydroxyl radicals (·OH) and atomic hydrogen to achieve >90% dehalogenation and >70% total organic carbon removal within 10 min. The resulting degradation intermediates possessed lower antibacterial activity than FLO and did not cause resistance gene proliferation in activated sludge. The Fenton-like activity of 3DP-Ni/Fe⁰ was similar across different shapes but increased with increasing porosity and size. Compared with powdered Ni/Fe⁰, 3DP-Ni/Fe⁰ exhibited faster electron transfer during Fe(II)/Fe(III) cycling, which increased the utilization efficiency of dissolved Fe²⁺ and H₂O₂ for ·OH production. Moreover, 3DP-Ni/Fe⁰ could be reused >150 times, 5-fold more than powdered Ni/Fe⁰, owing to its lower metal ion release and Fe⁰ depletion. 3DP-Ni/Fe⁰ with H₂O₂ can also efficiently remove chemical oxygen demand from real wastewater and other ROPs (e.g., acetaminophen, carbamazepine, thiamphenicol, and tetrabromobisphenol A).

100 Deals associated with Thiamphenicol

External Link

KEGG	Wiki	ATC	Drug Bank
D01407	Thiamphenicol	J01BA02	DB08621

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	-
Bacterial Infections	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis